Beyond Air, Inc.XAIR

Beyond Air, Inc. (XAIR) closed its latest fiscal year to March 31, 2026 with revenue of $7.7 million, a net loss of $33.2 million, and diluted EPS of -$4.01 against 8.3 million shares outstanding. The company’s operating loss of $29.0 million and negative operating cash flow of $18.1 million show a business that is still pre-commercial in every meaningful sense, despite the glossy LungFit brochures and the “All You Need Is Air” tagline. On current numbers, Beyond Air has generated $12.5 million in lifetime product sales, a figure that sits awkwardly beside the $10.2 million spent on R&D in the same period. (source: XAIR 10-K filing, https://www.sec.gov/Archives/edgar/data/1641631/000149315226030287/form10-k.htm)

Beyond Air’s core is the LungFit platform, a nitric-oxide delivery system designed for hospital and critical-care settings. The technology is real, the regulatory approvals are in place, and the company has a European competitor-Air Liquide’s KINOX™ platform-already selling a comparable product with a delivery infrastructure. Beyond Air’s filing warns that Air Liquide’s market presence “could impair our ability to complete our clinical trials or commercialize our approved product,” a sentence that reads less like competitive colour and more like a filing footnote that the board may wish it could quietly unpublish. (source: XAIR 10-K filing, https://www.sec.gov/Archives/edgar/data/1641631/000149315226030287/form10-k.htm)

Filings show total assets of $35.4 million against liabilities of $29.2 million, leaving shareholders’ equity at just $6.1 million. Cash and equivalents stand at $6.7 million, while the company burned $18.1 million in operating cash during the year and spent $1.0 million on property, plant, and equipment. Inventory fell by $1.1 million, which is either the result of efficient stock management or the first sign that demand is not yet matching the marketing claims. The 8-K filed on 9 July 2026 and the subsequent 13G filings note no material financing transactions in the period, meaning the company’s survival narrative continues to rely on future capital raises rather than operating cash generation. (source: XAIR 10-K filing, https://www.sec.gov/Archives/edgar/data/1641631/000149315226030287/form10-k.htm; XAIR 8-K filing, https://www.sec.gov/Archives/edgar/data/1641631/000149315226032621/form8-k.htm; XAIR Schedule 13G/A filing, https://www.sec.gov/Archives/edgar/data/1641631/000214438526000002/xslSCHEDULE_13G_X02/primary_doc.xml)

Trading activity is thin, with no chart context provided in the source rail and no evidence of a liquid market for the shares. The company’s market presence remains confined to regulatory filings, product pages, and press releases rather than exchange order books, so any attempt to read price action is speculation rather than evidence. The current disclosure set does not include volume, bid-ask spreads, or venue data, so investors are left to judge the company’s prospects on the numbers in the 10-K and the cautious language in the 8-Ks. (source: XAIR SEC submissions JSON, https://data.sec.gov/submissions/CIK0001641631.json)

Beyond Air’s ability to fund ongoing clinical work and potential expansion hinges on its next financing round, the timing and terms of which are not disclosed in the latest filings. The company’s cash runway is not quantified in the 10-K, and the absence of guidance on cash needs leaves shareholders navigating by filing footnotes rather than by management outlook. Until the company publishes a near-term cash forecast or a concrete path to profitability, the file remains a story of potential rather than performance. (source: XAIR 10-K filing, https://www.sec.gov/Archives/edgar/data/1641631/000149315226030287/form10-k.htm)

On the product front, the LungFit family is the only revenue-generating line disclosed, and the company’s website and press releases showcase the devices with promotional videos and family imagery. These materials prove a product exists and is marketed, but they do not prove market adoption, reimbursement coverage, or competitive pricing power against an incumbent like Air Liquide. (source: Products & Technology | Beyond Air Inc., https://www.beyondair.net/technology; Press Releases | Beyond Air Inc., https://www.beyondair.net/news-events/category/press-releases/)